The results of Mendez and Zavala study (2017) on 6 groups (proliferative endometrium, secretory endometrium, non-atypical hyperplasia, atypical hyperplasia, endometrioid and non-endometrioid carcinoma) showed leptin receptor down-regulation during the progression of endometrial carcinoma and its decrement in tumoral tissues compared to the normal tissue (28). This evidence concerns the gene LEPR and endometrial carcinoma.